CBDCA or CDDP/PEM/Bev as Induction Regimen Prior to Surgery in Patients With Non-SQ NSCLC Stage II and III

Trial Profile

CBDCA or CDDP/PEM/Bev as Induction Regimen Prior to Surgery in Patients With Non-SQ NSCLC Stage II and III

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms Modified NAVAL study
  • Most Recent Events

    • 01 Jul 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
    • 17 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top